Summary of Medical Aesthetics Industry Conference Call Industry Overview - The medical aesthetics industry is experiencing lower-than-expected performance in Q2 2025, primarily due to a decline in average transaction value (down 5% in April), a decrease in high-ticket project proportion, slower growth in first-tier cities, and increased regulatory scrutiny. As a result, mid-May revenue growth is only about 5% year-on-year, significantly below the expected target of 15% for the year [1][2][3]. Key Points and Arguments - **Revenue Growth and Customer Traffic**: April saw a revenue increase of only 3% year-on-year, failing to meet the 15% target. Customer traffic increased by 8%, but the continuous decline in average transaction value hindered overall revenue performance. The May holiday contributed somewhat, but revenue growth remained below expectations [2][3]. - **Customer Acquisition Challenges**: The proportion of new customers decreased year-on-year, with a 2% drop from January to April and a nearly 7% decline in April alone. The expected decrease during the May holiday is projected to be between 3% to 5% [1][10]. - **Product Performance**: - Collagen products are showing significant growth, with the Shanxi Jingbai Weimei series performing well, and the micro-aesthetic product line growing by 47%. - The botulinum toxin product line is experiencing stable growth of about 10%, while the hyaluronic acid product line shows mixed results, with brands like Juvederm and Restylane slowing down, and the HiTi series experiencing negative growth in April [1][12][13]. - **Market Dynamics**: The introduction of new brands like Aisufei is positively impacting the regenerative injection market, although traditional products like Bai Tian Shi are seeing a slowdown in sales. The company is considering introducing brands like Gaode Mei and Sofina Bodhi Source, which may disrupt existing products [1][15]. - **Promotional Activities**: March's promotional activities led to significant customer traffic growth, but the effectiveness of promotions in April and May was disappointing. High-ticket products like Tongyan Needle and Thermage are facing price declines due to increased competition, contributing to overall revenue slowdown [5][6]. - **Annual Performance Outlook**: Achieving the 15% annual performance target is challenging. The company plans to open new stores and hospitals and expand into untapped markets while promoting profitable products and controlling costs to maintain growth momentum [6][7]. Additional Important Insights - **Regulatory Impact**: Increased regulatory scrutiny is affecting marketing and product usage, contributing to the industry's overall performance challenges [4]. - **Emerging Products**: New products like the three-type humanized collagen gel from Weimei are expected to become market highlights, with a price point above 8,000 yuan, targeting the mid-face filling market [17][18]. - **Market Trends**: The market for collagen products is expanding, with a diverse range of offerings, including skincare and freeze-dried powders. Despite a decline in terminal prices, procurement prices have not decreased significantly, putting pressure on manufacturers to find alternatives [22][34]. - **Future Projections**: The botulinum toxin product line is expected to see continued growth, with new brands entering the market and a stable growth rate anticipated for 2025 and 2026 [26][27]. - **Compliance and Market Share**: Currently, compliant water light needles hold 0% market share, but this is expected to change as new registrations are approved, leading to a gradual increase in compliant product adoption [24]. This summary encapsulates the key insights and trends from the medical aesthetics industry conference call, highlighting the challenges and opportunities within the sector.

Core Viewpoint - The article addresses misleading perceptions in the capital market regarding hyaluronic acid and recombinant collagen, emphasizing the need to correct these misconceptions to avoid resource misallocation and risks for companies like Huaxi Bio [1][2]. Industry Perspective - Recombinant collagen is a small branch of collagen research and industrial transformation, with the main advancements still held by life science research institutions and pharmaceutical companies [1]. - In 2024, China's hyaluronic acid exports reached 161 tons, with 11.8 tons being high-end pharmaceutical-grade, while recombinant collagen exports were less than 0.02 tons, indicating a lack of market support for the notion that recombinant collagen is replacing hyaluronic acid [2][3]. - The growth rate for hyaluronic acid in the domestic and international markets is over 10%, with Huaxi Bio's pharmaceutical-grade hyaluronic acid showing over 20% growth, contradicting claims of market pressure [3]. Company Performance - Huaxi Bio's performance decline is attributed to a drop in consumer goods business and one-time asset impairment losses, rather than competition from recombinant collagen [3]. - The company maintains a high profit margin of around 50% across its active ingredient and medical terminal businesses, with significant revenue contributions from hyaluronic acid [3]. Market Dynamics - Recent successful companies in the skincare sector are not solely due to the rise of recombinant collagen but are also driven by strong e-commerce capabilities and complex formulations [4]. - The article highlights the misuse of the term "recombinant collagen" by some companies, which may mislead consumers and investors, emphasizing the need for a credible market environment [5][8]. Regulatory and Scientific Standards - There is a lack of detection standards for recombinant collagen, leading to the misuse of the term and potential consumer deception [8]. - The company advocates for a collaborative approach among professionals, testing institutions, and media to enhance understanding and improve the industry ecosystem [7][9].

Core Viewpoint - The article discusses the dual nature of the medical beauty (med-beauty) industry, highlighting the allure of quick beauty fixes against the backdrop of significant risks and potential irreversible consequences [3][7]. Industry Overview - The med-beauty industry has evolved from a focus on invasive procedures to a growing trend towards "light med-beauty," where consumers seek subtle enhancements rather than drastic changes [9][10]. - The core consumer demographic has shifted, with a notable increase in clients aged 35 to 45, while younger consumers are also increasingly engaging in anti-aging treatments [9][10]. Consumer Behavior - Many consumers initially pursue med-beauty treatments without adequate knowledge, often driven by trends and low prices, leading to potential risks [8][12]. - The rise of online platforms has exacerbated issues of low-quality products and services, with some institutions offering treatments at prices significantly below market value, raising concerns about product authenticity [13][20]. Risks and Accountability - The article emphasizes that the risks associated with med-beauty procedures are often downplayed, with many consumers unaware of the potential for severe complications, including permanent damage [12][18]. - Accountability in the event of treatment failures is complex, as consumers often receive treatments from various practitioners and products, making it difficult to trace responsibility [15][16]. Marketing and Trends - The marketing strategies in the med-beauty industry often exploit consumer insecurities, promoting treatments as "non-invasive" and "risk-free," which can be misleading [20][21]. - New trends and terminologies in the industry, such as "smile lip" and "elf ear," are often more about marketing than actual advancements in safety or efficacy [20][21]. Professional Standards - There is a significant disparity in the qualifications of practitioners within the industry, with many operators lacking formal medical training, which raises concerns about the quality of care [16][18]. - The article suggests that consumers should seek out specialists with proven expertise in specific procedures to mitigate risks [26][27].

Group 1 - The core point of the news is that Langzi Co., Ltd. plans to reduce its stake in Ruoyuchen by up to 3% within 15 trading days, following a previous cash-out of 217 million yuan, indicating a strategic move to support its expanding medical beauty business [1][4][6] - Ruoyuchen's stock price has surged by 534% over the past year, with a year-to-date increase of over 150%, prompting Langzi's decision to sell at a high point [1][4] - Langzi's investment in Ruoyuchen has yielded over 8 times returns, marking it as one of its most successful financial investments in recent years [4][6] Group 2 - Ruoyuchen, founded in 2011 and listed in September 2020, has seen a significant shift in its business structure, with traditional e-commerce operations declining while its own brand business is on the rise [4][5] - The revenue from Ruoyuchen's self-owned brands has grown from 73.97 million yuan in 2021 to approximately 263 million yuan in 2023, accounting for nearly 19.27% of total revenue [5] - The overall gross margin for Ruoyuchen reached 44.57% in 2024, with self-owned brands achieving a gross margin of 67%, significantly higher than its other business segments [5] Group 3 - Langzi's medical beauty business has become its main revenue driver, contributing 2.784 billion yuan in 2024, which is 48.92% of total revenue, surpassing its fashion women's wear segment [9][10] - Despite the growth, the gross margin for the medical beauty segment is only 54.42%, which is lower than the 63.45% margin for the women's wear segment [9][10] - Langzi's short-term borrowings have surged by 92.11% year-on-year, indicating increasing financial pressure as it expands its medical beauty operations [9][14] Group 4 - Langzi has faced compliance issues within its medical beauty operations, with several institutions under its umbrella encountering penalties for various violations [13] - The company is actively seeking funding to support its medical beauty expansion, which may include repaying upcoming debts and acquiring regional medical beauty institutions [13][14] - The medical beauty market in China has significant growth potential, with a penetration rate of only 3%-5%, compared to 20% in South Korea, but faces challenges from competitors and macroeconomic fluctuations [13][14]

Group 1 - Israel launched attacks on multiple targets in Iran, causing global stock indices to decline, with WTI crude oil futures surging nearly 14% and COMEX gold futures rising by 2% [1] - A-shares closed lower, with the Shanghai Composite Index down 0.75%, the Shenzhen Component down 1.10%, and the ChiNext Index down 1.13%. Sectors such as gold, oil, nuclear pollution prevention, and military industry saw significant gains [1] - The 62nd session of the "Digging Gold" competition concluded, with the champion achieving a return of 55.64%, the runner-up 48.48%, and the third place 46.61%. Participants capitalized on opportunities in blockchain, rare earth permanent magnets, and innovative pharmaceuticals [1][3] Group 2 - The competition is currently in a structural market phase, and participants can join a competition group to exchange valuable information and market insights [2] - The champion's successful investments included medical beauty stocks, agricultural chemicals, and rare earth permanent magnets, indicating strong market trend awareness [5] - Participants utilized "Fire Line Quick Review" to identify opportunities in innovative pharmaceuticals and silver sectors, with notable stocks performing well [6][8] Group 3 - The upcoming 63rd session of the competition will allow participants to simulate trading with a virtual capital of 500,000 yuan, with registration from June 14 to June 20 and the competition running from June 16 to June 20 [9] - Weekly cash rewards are available for positive returns, with the first place receiving 688 yuan and subsequent places receiving varying amounts [9][10] - Participants can gain access to "Fire Line Quick Review" for five days upon successful registration, with additional benefits for top performers [12]

Group 1 - The report maintains an overweight rating for the pharmaceutical and biotechnology industry, indicating a potential recovery and growth in the sector [3][7] - The SW pharmaceutical and biotechnology index increased by 6.61% from January to May 2025, outperforming the CSI 300 index by approximately 9.02 percentage points [9][17] - The industry valuation is currently at a relatively low level, with a PE ratio of approximately 50.45 times as of June 12, 2025, which is higher than the beginning of the year but still within the lower range historically [9][24] Group 2 - The report highlights that the 11th batch of national drug procurement is expected to commence in June 2025, with a focus on systemic anti-infection drugs [33][34] - The report emphasizes the ongoing optimization of policies supporting innovative drug development, which is expected to enhance the industry's growth [38][39] - The innovative drug sector is experiencing a significant increase in the proportion of First-in-Class new drug development, indicating improved quality and competitiveness [42][43] Group 3 - The global obesity population is projected to exceed 4 billion by 2035, driving demand for weight loss medications [54][55] - The market for GLP-1 drugs is rapidly expanding, with forecasts suggesting a market size exceeding $140 billion by 2030 [56][59] - GLP-1 drugs are continuously expanding their indications, showing efficacy in various chronic diseases beyond diabetes and weight loss [60][61] Group 4 - The report identifies key companies in the innovative drug sector, such as Heng Rui Medicine, which has shown significant revenue growth and a strong pipeline of innovative drugs [47][48] - The report notes that Heng Rui Medicine's revenue increased from 11.094 billion yuan in 2016 to 27.985 billion yuan in 2024, with a CAGR of 12.26% [48][49] - The company maintains a high level of R&D investment, with R&D expenses rising from 3.896 billion yuan in 2019 to 6.583 billion yuan in 2024, indicating a commitment to innovation [50][51]

Core Viewpoint - The article discusses the ongoing competition between two major players in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the market dynamics and the impact of recent controversies on their valuations and reputations [4][12][44]. Group 1: Market Dynamics - Huaxi Biological publicly criticized the notion that hyaluronic acid is outdated, directly targeting nine brokerage firms for their lack of rigor in research reports, which favored Juzhi Biological [4][12]. - Juzhi Biological's market capitalization has decreased significantly, dropping to approximately HKD 65 billion, a nearly one-third reduction from its peak on May 20 [8][46]. - The medical beauty market is experiencing rapid changes, with Juzhi Biological's revenue surpassing Huaxi Biological's in 2024, and its net profit being nearly twelve times that of Huaxi Biological [12][44]. Group 2: Controversies and Responses - Juzhi Biological faced allegations of product ingredient fraud, specifically regarding its core product, Kefu Mei, which is crucial for its revenue [6][29]. - The company initially responded slowly to the allegations, which led to investor dissatisfaction and a significant drop in stock price [28][29]. - Despite attempts to clarify the situation through third-party testing, Juzhi Biological's responses have been met with skepticism, particularly regarding the validity of their testing methods [26][27]. Group 3: Competitive Landscape - The competition between Huaxi Biological and Juzhi Biological is characterized as a market "replacement," with both companies vying for dominance in the medical beauty sector [13][44]. - Huaxi Biological's management attributes the market shift to capital chasing new trends, particularly the rise of collagen products over hyaluronic acid [44][45]. - The article emphasizes the fragility of the business models in the medical beauty industry, as both companies heavily rely on specific products, making them vulnerable to market changes [47][48].

Market Overview - The three major A-share indices experienced fluctuations today, with the Shanghai Composite Index down by 0.75%, the Shenzhen Component Index down by 1.1%, and the ChiNext Index down by 1.13%. The North Star 50 Index fell by 2.92%. The total market turnover reached 150.39 billion yuan, an increase of 20 billion yuan compared to the previous day, with over 4,400 stocks declining [1]. Sector Performance - Oil and gas, precious metals, nuclear pollution prevention, and military industry sectors showed strong performance, while consumer stocks experienced an overall pullback. Oil and gas stocks were particularly strong, with companies like Keli Co. and Shandong Molong hitting the daily limit. Gold stocks also performed well, with Western Gold reaching the daily limit and Xiaocheng Technology rising over 10%. Military stocks surged in the afternoon, with companies like Chenxi Aviation and Jieqiang Equipment hitting the daily limit. Conversely, liquor stocks were sluggish, with Huangtai Liquor and Jinhui Liquor dropping over 5%. The medical beauty sector faced significant declines, with Shuiyang Co. falling over 10% and other companies like Keka Co. and Huaye Fragrance also declining [2]. Hotspot Overview - The "Belt and Road" sector saw 14 stocks hitting the daily limit, with two stocks achieving consecutive limit-ups, the highest being three consecutive days. Notable stocks included Hars and Yong'an Pharmaceutical. The "Natural Gas" sector had 12 stocks hitting the daily limit, while the "Western Development" sector also had 12 stocks hitting the daily limit, with no consecutive limit-up stocks in either sector [8][9][10]. Market Trends - The oil and gas sector is gaining attention due to recent geopolitical events, including airstrikes by the air force on Iranian military targets, which led to a significant increase in international oil prices, with WTI crude oil futures rising by 10% to $74.99 per barrel, the highest since February 3 [11]. - The gold concept stocks are also in focus, as tensions surrounding Iran's nuclear program escalated, causing the Shanghai gold futures to rise by 2.46%, surpassing the 800 yuan mark for the first time since May 8 [12]. - The football concept stocks are gaining traction with the popularity of local football leagues, prompting discussions about hosting similar events in Sichuan province [13].

Core Viewpoint - The beauty industry is currently facing a significant controversy regarding the actual content of recombinant collagen, with a focus on the lack of standardized testing methods and criteria, which has led to a trust gap between brands and consumers [2]. Group 1: Industry Controversy - A beauty blogger reported that the recombinant collagen content in a popular product was only 0.0177%, significantly below the national standard of 0.1%, and failed to detect key amino acids like glycine [2]. - The controversy centers not on the technical routes or raw material sources, but on the choice of testing methods and the absence of unified standards, which has hindered the compliant development of the medical beauty industry [2]. Group 2: Regulatory Developments - Since 2022, the National Medical Products Administration (NMPA) has been releasing industry standards for recombinant collagen, including YY/T 1849-2022 and YY/T 1888-2023, to address the heterogeneity of recombinant collagen products [3]. - The introduction of mass spectrometry as a "gold standard" for quality control in recombinant collagen is expected to replace traditional methods that are susceptible to interference from other proteins [3]. Group 3: New Standards Implementation - On August 1, 2022, the NMPA implemented YY/T 1805.3-2022, which provides a high-specificity method for detecting collagen content using LC-MS/MS, addressing the limitations of traditional methods [4]. - A new standard, YY/T 1954-2025, for peptide fingerprint analysis of recombinant collagen is set to be implemented on March 1, 2026, which will enhance quality control and regulatory capabilities in the medical beauty industry [8]. Group 4: Industry Support and Collaboration - The Instrument Information Network is actively monitoring developments in cosmetic testing and promoting collaboration in the field, emphasizing the importance of advancements in testing technology and equipment [13].

Market Overview - The three major A-share indices collectively declined in the morning session, with the Shanghai Composite Index down 0.72%, the Shenzhen Component Index down 1.15%, and the ChiNext Index down 1.14% [1] - The total market turnover reached 936.1 billion yuan, an increase of 140 billion yuan compared to the previous day, with over 4,400 stocks declining [1] Sector Performance - The oil and gas, precious metals, and nuclear pollution prevention sectors showed strong gains, while the medical beauty, e-commerce, gaming media, and pharmaceutical sectors experienced significant declines [2] - Notable performers included Keli Co., Ltd. with a 30% limit up, and several other stocks in the oil and gas sector also hitting the limit up [2] - Precious metals stocks, such as Western Gold, also reached the limit up, while medical beauty concept stocks like Huaye Fragrance and Shuiyang Co. fell over 10% [2] Hot Topics - The "Belt and Road" initiative saw 12 stocks hitting the limit up, with two stocks achieving consecutive limit ups, including Hars Co. and Yong'an Pharmaceutical [8] - The Russia-Ukraine conflict concept had 9 stocks hitting the limit up, with representatives including Beiken Energy and Deshi Co. [8] - The natural gas sector also had 9 stocks hitting the limit up, with Beiken Energy and Deshi Co. as notable mentions [9] Specific Stock Movements - Keli Co., Ltd. led with a five-day limit up streak, while Hars Co. and Yingli Automotive achieved three consecutive limit ups [5][6] - Several stocks, including Xiamen Xinda and Annie Co., achieved two consecutive limit ups [7] News Impact - Oil prices surged following airstrikes on Iranian military facilities, with WTI crude oil futures rising 10% to $74.99 per barrel, the highest since February 3 [10] - Gold futures also saw a rise of 2.46%, surpassing the 800 yuan mark for the first time since May 8, amid escalating tensions in the Middle East due to Israeli airstrikes on Iran [11]